Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Safety and Clinical Effects of Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders). Pilot Study

To see complete record on, please visit this link

Id: NCT05137938

Organisation Name: Centre for Addiction and Mental Health

Overal Status: Recruiting

Start Date: October 25, 2021

Last Update: December 29, 2021

Lead Sponsor: Centre for Addiction and Mental Health

Brief Summary: Despite the known efficacy of pharmacotherapy (i.e. antidepressants) and psychotherapeutic interventions in treating depressive disorders, research evidence suggests that 20% to 40% of patients with major depressive disorder (MDD) do not respond adequately to such treatments. These patients are diagnosed with Treatment-Resistant Depression (TRD), and are sometimes treated with convulsive therapy. However, about 10-30% of TRD patients do not respond to convulsive therapy, and are thus diagnosed with Ultra-Resistant Depression (URD). Using an open label pilot study involving subjects, this trial aims to assess the safety, tolerability, and clinical effects of intranasal ketamine (IN) treatment in patients who do not respond to convulsive therapy. Intranasal ketamine (IN) treatment approach has shown promising therapeutic outcomes for patients with TRD, but has not yet been studied on patients with URD.

  • Depression

Total execution time in seconds: 0.20634508132935